Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

by Baranca Buijsers, Cansu Yanginlar, Marissa L. Maciej-Hulme, Quirijn de Mast, Johan van der Vlag
Published 2020-09-01

Selective Inhibition of Heparan Sulphate and Not Chondroitin Sulphate Biosynthesis by a Small, Soluble Competitive Inhibitor

by Marissa L. Maciej-Hulme, Eamon Dubaissi, Chun Shao, Joseph Zaia, Enrique Amaya, Sabine L. Flitsch, Catherine L. R. Merry
Published 2021-06-01

Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.

by Sarah L Berry, Hamza Hameed, Anna Thomason, Marissa L Maciej-Hulme, Somaia Saif Abou-Akkada, Paul Horrocks, Helen P Price
Published 2018-07-01

Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies

by Markus A. Loeven, Marissa L. Maciej-Hulme, Cansu Yanginlar, Melanie C. Hubers, Edwin Kellenbach, Mark de Graaf, Toin H. van Kuppevelt, Jack Wetzels, Ton J. Rabelink, Richard J. H. Smith, Johan van der Vlag
Published 2021-08-01

Increased Plasma Heparanase Activity in COVID-19 Patients

by Baranca Buijsers, Cansu Yanginlar, Aline de Nooijer, Inge Grondman, Marissa L. Maciej-Hulme, Inge Jonkman, Nico A. F. Janssen, Nils Rother, Mark de Graaf, Peter Pickkers, Peter Pickkers, Matthijs Kox, Matthijs Kox, Leo A. B. Joosten, Tom Nijenhuis, Mihai G. Netea, Mihai G. Netea, Luuk Hilbrands, Frank L. van de Veerdonk, Raphaël Duivenvoorden, Raphaël Duivenvoorden, Quirijn de Mast, Johan van der Vlag
Published 2020-10-01